09:45 AM EDT, 10/13/2025 (MT Newswires) -- Avidity Biosciences ( RNA ) said Monday it completed a positive pre-biologics license application meeting with the US Food and Drug Administration for its drug candidate delpacibart zotadirsen, or del-zota, to potentially treat Duchenne muscular dystrophy patients with exon 44 mutations. The company said it now plans to submit the BLA in Q1...

10:06 AM EDT, 10/13/2025 (MT Newswires) -- EHang ( EH ) said Monday it is launching a new-generation of long-range pilotless electric vertical take-off and landing aircraft, known as the VT35. The VT35 is an upgraded model designed for medium- to long-range applications like intercity, cross-sea, and cross-mountain transportation, the company said. EHang ( EH ) said the official price...

10:09 AM EDT, 10/13/2025 (MT Newswires) -- Palvella Therapeutics ( PVLA ) said Monday it has received the second year of funding under its US Food and Drug Administration Office of Orphan Products Development grant, supporting the company's ongoing phase 3 trial evaluating Qtorin 3.9% rapamycin anhydrous gel for the treatment of microcystic lymphatic malformations. The grant provides up to...

LONDON--(BUSINESS WIRE)--   FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Balyasny Asset Management LP (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee...